Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198

Breast Cancer Research and Treatment

Volumn 121, Issue 1, 2010, Pages 111-120

  Wolff, Antonio C ^a   Wang, Molin ^b   Li, Hailun ^b   Pins, Michael R ^c,g   Pretorius, Florence J ^d   Rowland, Kendrith M ^e   Sparano, Joseph A ^f   Davidson, Nancy E ^a,h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e Carle Clinic   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cardiotoxicity; Docetaxel; Metastatic breast cancer; Pegylated liposomal doxorubicin; Trastuzumab

Indexed keywords

DOCETAXEL; DOXORUBICIN; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EMBOLISM; EPIPHORA; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; THROMBOCYTE; THROMBOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENES, ERBB-2; HEART; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SYNDROME;

EID: 77951294720     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0838-7     Document Type: Article

References (34)

1. RP A'Hern IE Smith SR Ebbs 1993 Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens Br J Cancer 67 801 805 8471439
2. JM Nabholtz K Gelmon M Bontenbal, et al. 1996 Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer J Clin Oncol 14 1858 1867 1:CAS:528:DyaK28XjslOrsrg%3D 8656254
3. PM Ravdin HA Burris III G Cook, et al. 1995 Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 2879 2885 1:CAS:528:DyaK28XmslOntw%3D%3D 8523050
4. M Aapro 1998 Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group Semin Oncol 25 7 11 1:CAS:528:DyaK1MXitVCquw%3D%3D 9865705
5. GW Sledge D Neuberg P Bernardo, et al. 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 592 10.1200/JCO.2003.08.013 12586793 (Pubitemid 46621890)
6. Ghersi D, Wilcken N, Simes J et al (2005) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev CD003366
7. JA Sparano 1999 Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics Semin Oncol 26 14 19 1:CAS:528:DyaK1MXltVSltbs%3D 10426454
8. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 1:CAS:528: DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
9. AD Bangham RW Horne 1964 Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope J Mol Biol 8 660 668 10.1016/S0022-2836(64)80115-7 1:CAS:528:DyaF2cXktlers70%3D 14187392
10. G Berry M Billingham E Alderman, et al. 1998 The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin Ann Oncol 9 711 716 10.1023/A:1008216430806 1:STN:280:DyaK1cvhtFOmsA%3D%3D 9739435 (Pubitemid 28394155)
11. 2 Ann Oncol 11 1029 1033 10.1023/A:1008365716693 1:STN:280:DC%2BD3cvoslOrsQ%3D%3D 11038041
12. J Vaage E Mayhew D Lasic, et al. 1992 Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes Int J Cancer 51 942 948 10.1002/ijc.2910510618 1:STN:280: DyaK38zkvVSlsA%3D%3D 1639542
13. MA Amantea A Forrest DW Northfelt, et al. 1997 Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma Clin Pharmacol Ther 61 301 311 10.1016/S0009-9236(97)90162-4 1:CAS:528:DyaK2sXitlKks7s%3D 9084455 (Pubitemid 27145431)
14. A Gabizon R Catane B Uziely, et al. 1994 Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 987 992 1:CAS:528: DyaK2cXhslegs70%3D 8313389
15. Z Symon A Peyser D Tzemach, et al. 1999 Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes Cancer 86 72 78 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 1:CAS:528:DyaK1MXktleqtLc%3D 10391566 (Pubitemid 29293379)
16. JA Sparano EP Winer 2001 Liposomal anthracyclines for breast cancer Semin Oncol 28 32 40 1:CAS:528:DC%2BD3MXntFGgsL4%3D 11552228
17. ME O'Brien N Wigler M Inbar, et al. 2004 Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 440 449 10.1093/annonc/mdh097 14998846 (Pubitemid 38444547)
18. AM Keller RG Mennel VA Georgoulias, et al. 2004 Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer J Clin Oncol 22 3893 3901 10.1200/JCO.2004.08.157 1:CAS:528:DC%2BD2cXpsVKisbc%3D 15459210 (Pubitemid 41079870)
19. JA Sparano U Malik L Rajdev, et al. 2001 Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer J Clin Oncol 19 3117 3125 1:CAS:528:DC%2BD3MXltFektLg%3D 11408509
20. J Cortes S DiCosimo MA Climent, et al. 2009 Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study Clin Cancer Res 15 307 314 10.1158/1078-0432.CCR-08-1113 1:CAS:528:DC%2BD1MXhs1eruw%3D%3D 19118059
21. E Andreopoulou D Gaiotti E Kim, et al. 2007 Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer Clin Breast Cancer 7 690 696 10.3816/CBC.2007.n.028 1:CAS:528:DC%2BD2sXhtVOrsbbI 17919349
22. S Chia M Clemons LA Martin, et al. 2006 Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial J Clin Oncol 24 2773 2778 10.1200/JCO.2005.03.8331 1:CAS:528:DC%2BD28XntV2hu7o%3D 16682726 (Pubitemid 46630575)
23. E Stickeler M Klar D Watermann, et al. 2009 Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial Breast Cancer Res Treat 117 3 591 598 10.1007/s10549-008-0306-9 1:CAS:528:DC%2BD1MXhtFegtbfF 19156515
24. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 17159189 (Pubitemid 350003059)
25. E Nagore A Insa O Sanmartin 2000 Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management Am J Clin Dermatol 1 225 234 10.2165/00128071-200001040-00004 1:STN:280:DC%2BD3MnltVCjug%3D%3D 11702367
26. DM Vail R Chun DH Thamm, et al. 1998 Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model Clin Cancer Res 4 1567 1571 1:CAS:528:DyaK1cXktVWhtrw%3D 9626479
27. JA Sparano P Hu RM Rao, et al. 1999 Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study J Clin Oncol 17 3828 3834 1:CAS:528:DC%2BD3cXhsVChsA%3D%3D 10577856
28. JA Sparano A O'Neill PL Schaefer, et al. 2000 Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196 J Clin Oncol 18 2369 2377 1:CAS:528:DC%2BD3cXkvFWrsLY%3D 10856096
29. S Chan K Friedrichs D Noel, et al. 1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 2341 2354 1:CAS:528:DyaK1MXltlylt70%3D 10561296
30. JA Sparano AN Makhson VF Semiglazov, et al. 2009 Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study J Clin Oncol 27 4522 4529 10.1200/JCO.2008.20.5013 19687336
31. N Robert B Leyland-Jones L Asmar, et al. 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 2786 2792 10.1200/JCO.2005.04.1764 1:CAS:528:DC%2BD28XntV2hu7g%3D 16782917 (Pubitemid 46630577)
32. Pegram M, Forbes J, Pienkowski T et al (2007) BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 25(18S) (Abstract 1008)
33. Carrick S, Parker S, Wilcken N et al (2005) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev CD003372
34. AD Seidman 2003 Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? J Clin Oncol 21 577 579 10.1200/JCO.2003.10.086 12586789 (Pubitemid 46621886)